Life After Quanta and MedImmune: What You Need to Know About Patent Exhaustion and Licensing Now
Life After <i>Quanta and MedImmune</i>
October 7, 2008
Two recent Supreme Court decisions, Quanta Computer and MedImmune, have changed the landscape for patent licenses. License agreements may affect the ability to limit or pursue additional royalties from downstream users of patented technology. Merely approaching a party to start license negotiations can open the courthouse doors to a declaratory judgment, resulting in unwanted legal fees and jeopardizing the patent’s validity or enforceability
The panel addressed the real-world considerations facing intellectual property owners, licensors, licensees, and technology users in the aftermath of these decisions.
Presenters:
- George C. Best, Partner and member of Foley’s Intellectual Property Litigation and Appellate Practices
- Stephen P. Fox, Of Counsel to Foley’s Intellectual Property Department and Electronics Practice
- Doug Kundrat, Vice President, Deputy General Counsel & Director of Intellectual Property for Agilent Technologies, Inc.
Key topics included:
- New strategic considerations for patent licensing: perspectives of different industry groups
- Drafting licenses and analyzing patents to minimize exhaustion or to use exhaustion to protect downstream customers
- Using indemnity provisions in licenses and commercial agreements to your advantage
- Addressing MedImmune issues: Can you start licensing negotiations without risking a lawsuit?
- Using Quanta and MedImmune offensively or defensively in litigation
For questions about this program, please contact Zulaikha Rahim at [email protected].
Related Insights
May 29, 2026
Foley Viewpoints
SEC Proposes Significant Reforms to Registered Offering Framework
On May 19, 2026, the Securities and Exchange Commission (SEC) proposed sweeping amendments to its rules and forms governing registered…
May 29, 2026
Foley Corporate Governance Update
DExit One Year Later: An Assessment of SB21, the Continuing Pace of Reincorporation and the Maturation of Texas as a Corporate Domicile
When I last addressed the so-called DExit phenomenon, Delaware’s General Assembly had just enacted Senate Bill 21 in response to the growing concern that public companies, prompted by a series of decisions from the Delaware Court of Chancery, most prominently Tornetta v. Musk, were reconsidering their historical preference for incorporation in Delaware.
May 28, 2026
Foley Viewpoints
AI Transcription Tools in Health Care: What In-House Counsel Needs to Get Right
AI is changing health care faster than almost any other technology in recent memory. Among the most rapidly adopted applications are transcription tools that record encounters, convert speech to text, generate draft notes, and support scheduling, intake, triage, and other administrative workflows.